Identification

Name
Enalkiren
Accession Number
DB03395  (EXPT03298)
Type
Small Molecule
Groups
Experimental
Description
Not Available
Structure
Thumb
Synonyms
Not Available
External IDs
A-64662 / ABBOTT-64662
International/Other Brands
ENALKIREN
Categories
UNII
0U7YZ42Z47
CAS number
113082-98-7
Weight
Average: 656.8557
Monoisotopic: 656.426133554
Chemical Formula
C35H56N6O6
InChI Key
KQXVERRYBYGQJZ-WRPDIKACSA-N
InChI
InChI=1S/C35H56N6O6/c1-22(2)15-30(42)32(44)27(16-23-9-7-6-8-10-23)40-34(46)29(18-25-20-37-21-38-25)41-33(45)28(39-31(43)19-35(3,4)36)17-24-11-13-26(47-5)14-12-24/h11-14,20-23,27-30,32,42,44H,6-10,15-19,36H2,1-5H3,(H,37,38)(H,39,43)(H,40,46)(H,41,45)/t27-,28-,29-,30-,32+/m0/s1
IUPAC Name
3-amino-N-[(1S)-1-{[(1S)-1-{[(2S,3R,4S)-1-cyclohexyl-3,4-dihydroxy-6-methylheptan-2-yl]carbamoyl}-2-(1H-imidazol-5-yl)ethyl]carbamoyl}-2-(4-methoxyphenyl)ethyl]-3-methylbutanamide
SMILES
COC1=CC=C(C[C@H](NC(=O)CC(C)(C)N)C(=O)N[C@@H](CC2=CN=CN2)C(=O)N[C@@H](CC2CCCCC2)[C@@H](O)[C@@H](O)CC(C)C)C=C1

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
URenin
inhibitor
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
Azilsartan medoxomilThe risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Enalkiren is combined with Azilsartan medoxomil.
CandesartanThe risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Enalkiren is combined with Candesartan.
Candesartan cilexetilThe risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Enalkiren is combined with Candesartan cilexetil.
EprosartanThe risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Enalkiren is combined with Eprosartan.
FimasartanThe risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Enalkiren is combined with Fimasartan.
ForasartanThe risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Enalkiren is combined with Forasartan.
IrbesartanThe risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Enalkiren is combined with Irbesartan.
LosartanThe risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Enalkiren is combined with Losartan.
OlmesartanThe risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Enalkiren is combined with Olmesartan.
PitavastatinThe serum concentration of Pitavastatin can be decreased when it is combined with Enalkiren.
Food Interactions
Not Available

References

General References
  1. Glassman HN, Kleinert HD, Boger RS, Moyse DM, Griffiths AN, Luther RR: Clinical pharmacology of enalkiren, a novel, dipeptide renin inhibitor. J Cardiovasc Pharmacol. 1990;16 Suppl 4:S76-81. [PubMed:1705633]
External Links
KEGG Drug
D03738
KEGG Compound
C07466
PubChem Compound
60594
PubChem Substance
46505948
ChemSpider
54622
BindingDB
50006202
ChEBI
4787
ChEMBL
CHEMBL300337
Therapeutic Targets Database
DNC000604

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0122 mg/mLALOGPS
logP2.47ALOGPS
logP1.75ChemAxon
logS-4.7ALOGPS
pKa (Strongest Acidic)12.03ChemAxon
pKa (Strongest Basic)9.58ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count8ChemAxon
Hydrogen Donor Count7ChemAxon
Polar Surface Area191.69 Å2ChemAxon
Rotatable Bond Count18ChemAxon
Refractivity180.16 m3·mol-1ChemAxon
Polarizability72.65 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.6463
Blood Brain Barrier-0.9672
Caco-2 permeable-0.7867
P-glycoprotein substrateSubstrate0.8135
P-glycoprotein inhibitor INon-inhibitor0.7852
P-glycoprotein inhibitor IINon-inhibitor0.7862
Renal organic cation transporterNon-inhibitor0.8892
CYP450 2C9 substrateNon-substrate0.7924
CYP450 2D6 substrateNon-substrate0.7498
CYP450 3A4 substrateSubstrate0.6589
CYP450 1A2 substrateNon-inhibitor0.866
CYP450 2C9 inhibitorNon-inhibitor0.7568
CYP450 2D6 inhibitorNon-inhibitor0.8521
CYP450 2C19 inhibitorNon-inhibitor0.6809
CYP450 3A4 inhibitorNon-inhibitor0.5122
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6567
Ames testNon AMES toxic0.7827
CarcinogenicityNon-carcinogens0.9252
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.6931 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9939
hERG inhibition (predictor II)Non-inhibitor0.6604
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as hybrid peptides. These are compounds containing at least two different types of amino acids (alpha, beta, gamma, delta) linked to each other through a peptide bond.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Peptidomimetics
Sub Class
Hybrid peptides
Direct Parent
Hybrid peptides
Alternative Parents
Dipeptides / Phenylalanine and derivatives / Histidine and derivatives / N-acyl-alpha amino acids and derivatives / Alpha amino acid amides / Beta amino acids and derivatives / Amphetamines and derivatives / Phenoxy compounds / Methoxybenzenes / Anisoles
show 13 more
Substituents
Hybrid peptide / Alpha-dipeptide / Phenylalanine or derivatives / Histidine or derivatives / N-acyl-alpha amino acid or derivatives / Alpha-amino acid amide / Beta amino acid or derivatives / N-substituted-alpha-amino acid / Alpha-amino acid or derivatives / Amphetamine or derivatives
show 35 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
peptide (CHEBI:4787)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Receptor binding
Specific Function
Renin is a highly specific endopeptidase, whose only known function is to generate angiotensin I from angiotensinogen in the plasma, initiating a cascade of reactions that produce an elevation of b...
Gene Name
REN
Uniprot ID
P00797
Uniprot Name
Renin
Molecular Weight
45057.125 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Glassman HN, Kleinert HD, Boger RS, Moyse DM, Griffiths AN, Luther RR: Clinical pharmacology of enalkiren, a novel, dipeptide renin inhibitor. J Cardiovasc Pharmacol. 1990;16 Suppl 4:S76-81. [PubMed:1705633]

Drug created on June 13, 2005 07:24 / Updated on November 02, 2018 05:34